Cantor Fitzgerald Reiterates Their Buy Rating on KalVista Pharmaceuticals Inc (KALV)


In a report released yesterday, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on KalVista Pharmaceuticals Inc (KALV), with a price target of $32. The company’s shares closed yesterday at $16.62.

Duncan wrote:

“We reiterate our Overweight rating and 12-month price target of $32 on shares of KalVista. We recently hosted KalVista for investor meetings and came away with an increased conviction about KVD900, an orally administered plasma kallikrein inhibitor (PKal–inhib) as an emerging agent that could prove effective and safe in P2, has a high and could usher-in a paradigm shift in the acute treatment of HAE attacks. With increasing probability that notable value creation will occur with what may prove to be a “best-in-class” profile from an oral PKal-inhib, at least for acute HAE attack therapy, we see the potential for significant appreciation in KALV shares in 2019.”

According to TipRanks.com, Duncan is a 1-star analyst with an average return of -0.8% and a 44.0% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on KalVista Pharmaceuticals Inc is a Moderate Buy with an average price target of $31.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.57 and a one-year low of $7.73. Currently, KalVista Pharmaceuticals Inc has an average volume of 64.66K.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. It offers small molecule plasma kallikrein for the treatment of hereditary angioedema; diabetic macular edema; and other plasma kallikrein-associated diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts